TY - JOUR
T1 - Sympathovagal imbalance in acromegalic patients
AU - Resmini, Eugenia
AU - Casu, Massimo
AU - Patrone, Vittoriana
AU - Murialdo, Giovanni
AU - Bianchi, Federico
AU - Giusti, Massimo
AU - Ferone, Diego
AU - Minuto, Francesco
PY - 2006/1
Y1 - 2006/1
N2 - Context: Sympathovagal imbalance is a common finding in diabetes and is considered to be a cardiovascular risk factor. No data are available on sympathovagal balance (SB) in acromegalic patients. Objective: The objective of this study was to evaluate SB in acromegalic patients. Patients: Twenty nondiabetic, nonhypopituitary, acromegalic patients (13 women and seven men; mean age ± SEM, 51.30 ± 3.09 yr) were compared with age-matched subjects (21 normal subjects, 20 patients with type 1 diabetes mellitus, and 15 patients with type 2 diabetes mellitus). Interventions: Autonomic tests, used to evaluate SB, were performed by power spectral analysis of heart rate variability in clinostatism (c) and orthostatism (o), using a frequency domain method. Power spectral analysis identifies peaks of power: high frequency (HF), which expresses vagal activity, and low frequency (LF), which expresses sympathetic activity. Results: Acromegalic patients displayed significantly lower LFc/HFc (P = 0.002) and LFo/HFo (P <0.001) ratios than normal subjects. HFo was significantly higher in acromegalic patients than in normal subjects (P <0.001) and patients with type 1 diabetes mellitus (P = 0.004), but no different from that in type 2 diabetes mellitus patients (P = 0.069). In untreated acromegalic patients, the alterations found in the whole group were confirmed; no statistically significant differences were found between untreated acromegalic patients and those treated with somatostatin analogs. Similarly, the same alterations found in the whole group were evident in the controlled acromegalic patients, and no significant differences were found between controlled and uncontrolled patients. Conclusion: Our study evidenced that sympathovagal imbalance in acromegalic patients, due to vagal hypertone, is difficult to reverse and is not influenced by medical therapy. This could be a new cardiovascular risk factor.
AB - Context: Sympathovagal imbalance is a common finding in diabetes and is considered to be a cardiovascular risk factor. No data are available on sympathovagal balance (SB) in acromegalic patients. Objective: The objective of this study was to evaluate SB in acromegalic patients. Patients: Twenty nondiabetic, nonhypopituitary, acromegalic patients (13 women and seven men; mean age ± SEM, 51.30 ± 3.09 yr) were compared with age-matched subjects (21 normal subjects, 20 patients with type 1 diabetes mellitus, and 15 patients with type 2 diabetes mellitus). Interventions: Autonomic tests, used to evaluate SB, were performed by power spectral analysis of heart rate variability in clinostatism (c) and orthostatism (o), using a frequency domain method. Power spectral analysis identifies peaks of power: high frequency (HF), which expresses vagal activity, and low frequency (LF), which expresses sympathetic activity. Results: Acromegalic patients displayed significantly lower LFc/HFc (P = 0.002) and LFo/HFo (P <0.001) ratios than normal subjects. HFo was significantly higher in acromegalic patients than in normal subjects (P <0.001) and patients with type 1 diabetes mellitus (P = 0.004), but no different from that in type 2 diabetes mellitus patients (P = 0.069). In untreated acromegalic patients, the alterations found in the whole group were confirmed; no statistically significant differences were found between untreated acromegalic patients and those treated with somatostatin analogs. Similarly, the same alterations found in the whole group were evident in the controlled acromegalic patients, and no significant differences were found between controlled and uncontrolled patients. Conclusion: Our study evidenced that sympathovagal imbalance in acromegalic patients, due to vagal hypertone, is difficult to reverse and is not influenced by medical therapy. This could be a new cardiovascular risk factor.
UR - http://www.scopus.com/inward/record.url?scp=30344446340&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=30344446340&partnerID=8YFLogxK
U2 - 10.1210/jc.2005-1506
DO - 10.1210/jc.2005-1506
M3 - Article
C2 - 16263819
AN - SCOPUS:30344446340
VL - 91
SP - 115
EP - 120
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 1
ER -